Journal of Oncology / 2019 / Article / Fig 4

Research Article

Overexpression of DCLK1-AL Increases Tumor Cell Invasion, Drug Resistance, and KRAS Activation and Can Be Targeted to Inhibit Tumorigenesis in Pancreatic Cancer

Figure 4

Overexpression of DCLK1-AL in pancreatic cancer cells increases cell invasion, drug resistance, and KRAS activation. (a) Both AsPC-1 and MP2 cells were infected with lentivirus containing either DCLK1-AL-RFP or RFP cDNA sequence to establish stable cell lines overexpressing DCLK1. (b) Matrigel coated transwell assays were used to study cell invasion activity. (c) Overexpression of DCLK1-AL increases pancreatic cancer cell resistance to Gemcitabine. (d) DCLK1-AL forms a complex with RAS. (e) Overexpression of DCLK1AL increases active RAS in pancreatic cancer cells. (f-g) Overexpression of DCLK1-AL increases pancreatic cancer cell resistance to Everolimus, ABT-199, and LY-294002.

(a)
(b)
(c)
(d)
(e)
(f)
(g)

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.